Yi Qing
Myeloma Institute for Research and Therapy and Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA.
Expert Rev Vaccines. 2003 Jun;2(3):391-8. doi: 10.1586/14760584.2.3.391.
Multiple myeloma is still a fatal disease. Despite advances in high-dose chemotherapy supported by autologous transplantations, relapse of the underlying disease remains the primary cause of treatment failure. Strategies for post-transplantation immunomodulation would be desirable for eradication of remaining tumor cells. Toward this end, immunotherapy aimed at inducing myeloma-specific immunity in patients has been exploited. Idiotype protein, secreted by myeloma cells, has been the main target for immunotherapy as it is the best-defined, tumor-specific antigen. The focus of this review article is the use of idiotype as a form of protein antigen to immunize patients, to load dendritic cells, or as part of DNA vaccines. Various strategies of immunotherapy and the outcome of clinical trials are also discussed.
多发性骨髓瘤仍然是一种致命疾病。尽管在自体移植支持下的大剂量化疗取得了进展，但潜在疾病的复发仍然是治疗失败的主要原因。移植后免疫调节策略对于根除残留肿瘤细胞是可取的。为此，已探索了旨在诱导患者骨髓瘤特异性免疫的免疫疗法。骨髓瘤细胞分泌的独特型蛋白一直是免疫疗法的主要靶点，因为它是定义最明确的肿瘤特异性抗原。本文综述的重点是使用独特型作为蛋白质抗原的一种形式来免疫患者、负载树突状细胞或作为DNA疫苗的一部分。还讨论了各种免疫治疗策略和临床试验结果。
